
-
Valneva SE NasdaqGS:VALN Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France.
Location: 6 rue Alain Bombard, Saint-Herblain, 44800, France | Website: https://valneva.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.043B
Cash
153M
Avg Qtr Burn
-11.73M
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
0.82%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IXCHIQ (VLA1553) Details Chikungunya, Infectious disease | Approved Quarterly sales | |
IXCHIQ (VLA1553) Details Chikungunya, Viral infection | Phase 3 Update | |
IXCHIQ (VLA1553) Details Chikungunya, Viral infection | Phase 3 Initiation | |
IXCHIQ (VLA1553) Details Chikungunya, Viral infection | Phase 3 Initiation | |
Shigella4V2 (S4V2) Details Shigella, Nasolabial fold lines | Phase 2 Data readout | |
VLA15 Details Lyme disease, Bacterial infection | Phase 2 Data readout | |
VLA1601 Details Viral infection, Zika virus | Phase 1 Data readout | |
VLA2001 Details Infectious disease, COVID-19 | Failed Discontinued |